Please assess the completion status of the following clinical trial:

Trial Title: Canadian Pegvisomant Compassionate Study In Acromegalic Patients

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Subjects must have participated and completed the previous Pegvisomant studies or have shown to be unresponsive to other conventional therapies~Exclusion Criteria:~* ALT/AST\>3 times the ULN or have hepatic disease~* have severe visual field loss, cranial nerve palsies or intracranial HTN that requires surgery to decompress the tumor~* unwilling to self-administer the medication.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).